NCT05923814

Humanized Anti-CD25 Antibody for Prophylaxis of aGVHD in Elderly Underwent HID-HSCT

The Administration of Humanized Anti-CD25 Antibody for Prophylaxis of aGVHD in Patients Older Than 50y Underwent HID-HSCT

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

Age is no longer a barrier to successful allogeneic hematopoietic cell transplantation. However, the incidence of aGVHD is still high among the elderly, especially for patients receiving HID-HSCT. We designed this clinical trial to use humanized CD25 antibody for aGVHD prophylaxis among in elderly patients aged 50 and older. The humanized CD25 antibody was administered at 1 mg/kg iv on days+1 and +4 after HSCT.

Conditions

• The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT

Interventions

Type	Name	Description
DRUG	CD25 prophylaxis	The humanized CD25 antibody was administered at 1 mg/kg iv on days+1 and +4 after HSCT.

Timeline

• Start date: 2023-07-07
• Primary completion: 2024-05-07
• Completion: 2024-05-07
• First posted: 2023-06-28
• Last updated: 2023-06-28

Regulatory

• FDA-regulated drug study